Extended Data Fig. 2: Antitumor activity.
From: Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Best percentage changes in target lesions in dose escalation stage and each of the 4 cohorts (n = 90). The patients without tumor type labeled were GC/GEJ.
